A Comparison of Entecavir and Lamivudine for the Prophylaxis of Hepatitis B Virus Reactivation in Solid Tumor Patients Undergoing Systemic Cytotoxic Chemotherapy-Reference-Cited by-同舟云学术

A Comparison of Entecavir and Lamivudine for the Prophylaxis of Hepatitis B Virus Reactivation in Solid Tumor Patients Undergoing Systemic Cytotoxic Chemotherapy

Published:2015-06-29 Issue:6 Volume:10 Page:e0131545
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Chen Wen-Chi,Cheng Jin-Shiung,Chiang Po-Hung,Tsay Feng-Woei,Chan Hoi-Hung,Chang Hsueh-Wen,Yu Hsien-Chung,Tsai Wei-Lun,Lai Kwok-Hung,Hsu Ping-I

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference36 articles.

1. Hepatitis B virus infection;YF Liaw;Lancet,2009

2. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy;JH Hoofnagle;Ann Intern Med,1982

3. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study;AS Lok;Gastroenterology,1991

4. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors;W Yeo;J Med Virol,2000

5. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy;W Yeo;Hepatology,2006

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatitis B Virus Reactivation in Cancer Patients Receiving Chemotherapy—A Systematic Review and Meta-Analysis;Seminars in Oncology;2024-08

2. Risk of hepatitis B virus reactivation in cancer patients undergoing treatment with tyrosine kinase-inhibitors;World Journal of Gastroenterology;2024-06-28

3. Navigating the complex terrain of hepatitis B virus reactivation in the era of Bruton tyrosine kinase inhibitors;World Journal of Gastroenterology;2024-06-07

4. A Review of Hepatitis B Reactivation Risk on Immunosuppressants with a Focus on Newer Immunomodulators;Current Hepatology Reports;2024-02-28

5. Consensus Guidelines: Best Practices for the Prevention, Detection and Management of Hepatitis B Virus Reactivation in Clinical Trials with Immunosuppressive/Immunomodulatory Therapy;Drug Safety;2024-02-14